Clinic Roundup

• Resverlogix Corp., of Calgary, Alberta, said it started a Phase II trial in patients with pre-diabetes mellitus to examine the effects RVX-208 and ApoA-I production on glucose metabolism. The trial is being conducted in collaboration with Baker IDI Heart & Diabetes Institute in Melbourne, Australia, and will examine insulin secretion, insulin sensitivity and other parameters. Twenty patients will be enrolled, with data expected in the first half of 2014. RVX-208 is a small molecule designed to inhibit BET bromodomains.